Pharmeasy

Drug, medical services firm PharmEasy may lay off hundreds of employees

The company has a total workforce of about 1500

Snapdeal defers $152 mn IPO indefinitely citing poor market conditions

Development follows shelving of IPO plans by several notable firms such as Image Marketing (owner of wearable brand Boat), Droom Technology and PharmEasy

Prosus posts $80-million loss on investment in PayU India

Technology investor Prosus on Wednesday reported widening of its consolidated trading loss to USD 80 million, about Rs 654 crore, on account of investment in PayU India business during first half of the current fiscal. The Netherlands-based investor firm, however, registered a 59 per cent growth in total payments volume (TPV) at USD 28 billion, about Rs 2.29 lakh crore, in India. PayU revenue increased to USD 183 million, about Rs 1,497 crore. "Consolidated trading losses expanded to USD 80 million, as we continued to invest in growing our credit operations in India. In India, our largest payments market, TPV grew 59 per cent to USD 28 billion, and revenue increased 48 per cent to USD 183 million, following increased digitalisation in e-commerce, financial services and bill payments, and a rebound in post pandemic travel," the company said. The Prosus group's overall trading loss widened to USD 1.4 billion during the reported period from USD 2.8 billion a year ago. The revenue of

Withdrawal of start-up IPOs take wind out of sails of unlisted market

Share prices, trading activity slump amid rising uncertainty for startup listings

South Korea's KB Group invests $100 mn in Elev8 Venture Partners Fund

Financing will help Elev8 identify investment opportunities in Indian technology companies

EvolutionX Debt Capital makes maiden investment in PharmEasy parent firm

Debt financing platform's investment amount was not revealed; it will make equity infusion later

Boat joins PharmEasy, Droom to shelve listing plans amid valuation concerns

Rising Sebi scrutiny, poor investor response during roadshows seen as reasons for withdrawal by companies

'Brand Aamir' in the soup over ad controversy. Can he bounce back?

Actor facing flak for ad for AU Small Finance Bank; not new to controversy, which could affect brand value, say experts

Primary market revival is still some time away, say analysts

Inflation trajectory and the actions of global central banks, especially the US Fed will be keenly watched by market participants. In this backdrop, primary markets will remain in wait and watch mode

PharmEasy listing pull-out a sign of start-up fatigue: Market experts

Shares of new-age companies have dropped more than 60% amid liquidity squeeze.

PharmEasy calls off its public offer; to go for rights issue instead

API Holdings, the parent company of PharmEasy, wrote to shareholders announcing withdrawal of DRHP

PharmEasy plans $200 million fund raising at lower valuation: Report

Indian drug and medical services startup PharmEasy is in talks with investors to raise $200 million, but at a valuation that could be 15% or even 25% lower than last year's $5.1 billion

Cars24 to Vedantu, start-up lay-offs accelerate on capital crunch worries

Falling valuations, slowing funding rounds add to woes; move aimed at conserving cash and shore up profitability

After 2021 boom, how 2022 could be a year of reckoning for Indian startups

After the boom of 2021, when 44 Indian startups became unicorns, the markets are more selective and investors less enthusiastic in participating at unrealistic valuations

SoftBank-backed Oyo to weigh 50% smaller IPO amid market turmoil: Report

Oyo made preliminary filings in September aiming for an IPO in early 2022

Sebi tightens IPO valuation scrutiny, jolts startups eyeing listing: Report

Sebi probing IPO-bound firms on non-financial metrics, says report; the push comes after Paytm's IPO debacle

PharmEasy parent API Holdings gets Sebi nod for Rs 6,250-cr IPO

API Holdings, the parent company of PharmEasy, Adar Poonawalla-backed Wellness Forever Medicare and metal recycling firm CMR Green Technologies received Sebi's nod for IPOs

Dozen Indian IPOs now under extra investor scrutiny after Paytm debacle

Planned smaller IPOs could have a harder time pricing shares if there is a reduced appetite for new listings

Early mover advantage and scale key themes for PharmEasy investors

Success depends on its ability to integrate various entities across the healthcare value chain

PharmEasy parent files for IPO; looks to garner Rs 6,250 crore

The issue will comprise only primary share sale